leisure time -WSS

leisure time

author：leisure time 2025-10-02 10:38:39 - browse：4587

Adam's take main illustration — Molly Ferguson/STAT

Hello! Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale.

Gilead needs Arcellx more than ever

The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business. Strategically, does it make sense for Gilead to invest even more in antibody-drug conjugates like Trodelvy, where its lackluster profile and increased competition overall makes winning seem unlikely? Or, should Gilead double down on its Kite division and CAR-T cell therapy — the type of cancer treatments where it truly excels?

If the answers to those questions are no and yes (I lean that way), then Gilead’s current partnership with Arcellx, which is developing a BCMA-targeted CAR-T therapy for multiple myeloma, becomes a lot more important.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Multiple sclerosis has subtypes with different best treatments: study

WSS

American taxpayers paid $1.8 trillion in health care costs in 2022

JPM pitch from hospitals? Revenue streams outside of patient care

Pancreatic cancer is often deadly, but new discoveries are raising hope

Oral obesity drug from Viking Therapeutics hits key early target

Allen Institute goes after foundational questions, CEO Costa says

Multiple sclerosis has subtypes with different best treatments: study

hotspot

leisure time

Gilead needs Arcellx more than ever

focus

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

People with mental disorders often marry others with same

Medical records are filled with copy

Merck to acquire Harpoon Therapeutics for $680 million

Dobbs anniversary: the lost opportunity of abortion as health care

Florida Supreme Court upholds state's abortion ban

Medical records are filled with copy

American taxpayers paid $1.8 trillion in health care costs in 2022

Hepatitis C has a cure — but many Americans still lack access to it

Multiple sclerosis has subtypes with different best treatments: study

leisure time

Overprescribed: High cost isn't America's only drug problem

JPM pitch from hospitals? Revenue streams outside of patient care

Medicare Advantage overpayments discussion gets experts fired up

Male doctors called my cancer incurable. A female doctor showed it wasn't

Gene therapy denied for Afghan refugee whose father aided U.S.

Ascension's ugly legal battle over care for poor patients in Texas

explore

leisure time

hotspot

entertainment